Gilead Sciences, Inc (GIS) Stock Price & News

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade. In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100. The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia

About Gilead Sciences, Inc

CEODaniel O'Day

Employees17 мян

Founded1987 оны 6-р сарын 22

HeadquartersFoster City, Калифорни, Америкийн Нэгдсэн Улс

Sector-

Websitegilead.com

All values in USD	2025 оны 9-р сар	2025 оны 12-р сар	2026 оны 3-р сар	2026 оны 6-р сар
Revenue	7.77 тэрбум	7.92 тэрбум	6.96 тэрбум	7.80 тэрбум
Cost of goods sold	1.57 тэрбум	1.62 тэрбум	1.44 тэрбум	1.58 тэрбум
Cost of revenue	1.57 тэрбум	1.62 тэрбум	1.44 тэрбум	1.58 тэрбум
Research and development expenses	1.33 тэрбум	1.57 тэрбум	1.36 тэрбум	1.69 тэрбум
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1.35 тэрбум	1.78 тэрбум	1.43 тэрбум	1.91 тэрбум
Operating expense	2.69 тэрбум	3.34 тэрбум	2.78 тэрбум	3.60 тэрбум
Total operating expenses	4.26 тэрбум	4.96 тэрбум	4.23 тэрбум	5.18 тэрбум
Operating income	3.51 тэрбум	2.96 тэрбум	2.73 тэрбум	2.63 тэрбум
Other non operating income	-23.00 сая	51.00 сая	-8.00 сая	-
EBT including unusual items	3.64 тэрбум	2.08 тэрбум	2.58 тэрбум	-10.25 тэрбум
EBT excluding unusual items	3.34 тэрбум	2.80 тэрбум	2.59 тэрбум	2.42 тэрбум
Income tax expense	589.00 сая	-105.00 сая	559.00 сая	242.00 сая
Effective tax rate	16.18%	-5.05%	21.67%	-2.36%
Other operating expenses	-	-	-	-
Net income	3.05 тэрбум	2.18 тэрбум	2.02 тэрбум	-10.50 тэрбум
Net profit margin	39.28%	27.55%	29.04%	-134.51%
Earnings per share	2.47	1.86	2.03	-6.75
Interest and investment income	88.00 сая	95.00 сая	95.00 сая	45.00 сая
Interest expense	-256.00 сая	-255.00 сая	-240.00 сая	-247.00 сая
Net interest expenses	-168.00 сая	-160.00 сая	-145.00 сая	-202.00 сая
Depreciation and amortization charges	-	-	-	-
EBITDA	4.20 тэрбум	3.65 тэрбум	3.42 тэрбум	3.33 тэрбум
Gain or loss from assets sale	-	-	-	-

Ask anything